Royalty Pharma plc EBIT Margin for the Trailing 12 Months (TTM) ending March 31, 2025: 72.05%

Royalty Pharma plc EBIT Margin is 72.05% for the Trailing 12 Months (TTM) ending March 31, 2025, a 195.27% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.
  • Royalty Pharma plc EBIT Margin for the Trailing 12 Months (TTM) ending March 31, 2024 was 24.40%, a 10.67% change year over year.
  • Royalty Pharma plc EBIT Margin for the Trailing 12 Months (TTM) ending March 31, 2023 was 22.05%, a -62.66% change year over year.
  • Royalty Pharma plc EBIT Margin for the Trailing 12 Months (TTM) ending March 31, 2022 was 59.04%, a -15.67% change year over year.
  • Royalty Pharma plc EBIT Margin for the Trailing 12 Months (TTM) ending March 31, 2021 was 70.01%, a -48.45% change year over year.
Key Data
Date EBIT Margin EBITDA Margin Net Income Margin EBT Margin